Lyka Labs Ltd LYKALABS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₹86.04
- Day Range
- ₹84.32–84.32
- 52-Week Range
- ₹44.10–98.90
- Bid/Ask
- ₹84.32 / ₹84.32
- Shares Outstanding
- 36.15M
- Market Cap
- ₹3.05B
- Volume/Avg
- 2,536 / 22,117
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.35%
Company Profile
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 499
- Website
- https://www.lykalabs.com
Valuation
|
Metric
|
LYKALABS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.34 |
Price/Sales | 2.21 |
Price/Cash Flow | 69.53 |
Price/Earnings
LYKALABS
Financial Strength
|
Metric
|
LYKALABS
|
|---|---|
Quick Ratio | 0.75 |
Current Ratio | 1.17 |
Interest Coverage | −2.37 |
Quick Ratio
LYKALABS
Profitability
|
Metric
|
LYKALABS
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
LYKALABS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$V&zKk | LOCK|vW>?D | $130B | |||
| Moderna Inc
MRNA
| LOCK|vh^BZ%s | LOCK|Vc< | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|r@^?bSK | LOCK|>$p!G | $83B | |||
| argenx SE ADR
ARGX
| LOCK|h@^^T^ | LOCK|JH | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|GG@<HW% | LOCK|?N | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|s#^%Gc | LOCK|hg!WW | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<#@<@sVC | LOCK|>L!> | $28B | |||
| Incyte Corp
INCY
| LOCK|&JKMfd | LOCK|>? | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|%@##t$@ | LOCK|?< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@@cG#f | LOCK|Lk | $14B |
United States